BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

SuperNova Diagnostics to Present at the Rodman & Renshaw Global Investment Conference


9/6/2011 1:24:15 PM

WASHINGTON, LONDON and HONG KONG, Sept. 6, 2011 /PRNewswire/ -- SuperNova Diagnostics®, Inc., a privately-held global diagnostics company for human and non-human health applications, today announced that Neil J. Campbell, President and CEO, will be presenting at the Rodman & Renshaw Global Investment Conference on September 13, 2011 from 10:50 -11:15 am EDT in the Metropolitan West room of the Waldorf-Astoria in New York, NY.

The presentation will include an overview of SuperNova's proprietary point-of-care (POC) and point-of-use (POU) diagnostic technology targeting four industry sectors: human health, animal health, industrial and biodefence/biosecurity. A live webcast and 90 day archive of the presentation will be available at http://www.wsw.com/webcast/rrshq20/spdi.

"Point-of-care and point-of-use diagnostics represent a multi-billion dollar market with an annual growth rate of 20 percent, making it one of the most significant investing and technological opportunities over the next five to 10 years," said Mr. Campbell. "SuperNova is at the forefront of this revolution, having developed our AmpCrystal® platform to provide an array of diagnostic capabilities, from patient treatment to pathogen detection. We welcome the opportunity to showcase our vision and technology to the many investors and industry leaders at the Rodman & Renshaw Global Investment Conference."

About SuperNova Diagnostics®, Inc.

SuperNova® is a development-stage diagnostics company with a proprietary platform for conducting diagnostics at the site of interest with point-of-care in human health and point-of-use for non-human health applications. A powerful proprietary nanochemistry, AmpCrystal®, can deliver novel, next generation performance for pathogens, proteins, and directly measure DNA without PCR with ultra-low sensitivity and specificity while not sacrificing a dynamic range of measurements. SuperNova can be utilized in a wide range of diagnostic formats (lateral flow, self-contained cartridges, microtitre, microarrays, closed systems, research products and OEM). SuperNova® Putting the Laboratory in the Palm of Your Hand®. For additional information, please visit www.supernovadiagnostics.com.

Media Contacts:
Tiberend Strategic Advisors, Inc.
Jason Rando
(212) 827-0020
jrando@tiberend.com

SOURCE SuperNova Diagnostics, Inc.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->